BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model
- 1 February 2011
- journal article
- Published by Elsevier in Neurobiology of Disease
- Vol. 41 (2) , 353-360
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- In Vivo Structure−Activity Relationship Study of Dorsomorphin Analogues Identifies Selective VEGF and BMP InhibitorsACS Chemical Biology, 2009
- Bone morphogenetic protein receptors and signal transductionThe Journal of Biochemistry, 2009
- BMP type I receptor inhibition reduces heterotopic ossificationNature Medicine, 2008
- Structure–activity relationship study of bone morphogenetic protein (BMP) signaling inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Myostatin Directly Regulates Skeletal Muscle FibrosisJournal of Biological Chemistry, 2008
- Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitorsProceedings of the National Academy of Sciences, 2008
- Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx miceJournal of the Neurological Sciences, 2008
- Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolismNature Chemical Biology, 2007
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist GremlinJournal of Cell Biology, 2006